Thursday, June 25th at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST
Cardiac drug discovery increasingly depends on models that reflect human physiology without sacrificing scalability or reproducibility. Yet many in vitro cardiac systems still force teams to choose between biological relevance and throughput, making it difficult to generate data that remains reliable across screening, validation, and translational studies.
For discovery and safety teams, this creates pressure to identify models that not only capture complex cardiac biology, but also support automation, assay consistency, and large-scale screening workflows.
In this webinar, we focus on how physiologically relevant 3D iPSC-based cardiac microtissues can support high-throughput drug discovery, disease modeling, and cardiotoxicity assessment while reducing variability and operational complexity.
Key learning objectives
- 3D cardiac microtissues can improve physiological relevance compared to traditional 2D
assays - Automated workflows enable scalable and reproducible high-throughput cardiac
screening - Multi-cell type iPSC-based models provide deeper insights into cardiac function and
disease mechanisms - Disease-specific cardiac microtissues support arrhythmia modeling and large-scale
compound screening - Integrated automated pipelines can accelerate drug discovery while maintaining assay
robustness
Register to learn how to implement an integrated early safety strategy and assess how this approach could increase your biotherapeutics’ chances of clinical success.
Who should attend?
If you work in cardiac drug discovery, preclinical safety, disease modeling, or high-throughput screening, this webinar is designed for you. Whether you are in pharma, biotech, or academia, the session will be especially relevant if you are looking for more physiologically relevant cardiac models that can also support scalable and reproducible screening workflows.
Register to learn how automated 3D cardiac microtissue platforms can support scalable cardiac screening and evaluate how physiologically relevant models could strengthen your discovery workflows
Speakers
Silke holds a PhD in cell biology and immunology from the University of Hannover, Germany, and has over 20 years of experience in stem cell-based models for drug discovery. She is passionate about developing and applying functional iPSC cardiomyocyte assays to assess the efficacy and safety of novel drug therapies. Before joining Ncardia, Silke led cross-functional teams at stem-cell technology companies and worked as an independent scientific consultant for eight years, providing expertise in assay development for drug discovery and toxicology. At Ncardia, Silke applies her extensive experience to advance innovative toxicology solutions, supporting the development of safer and more effective therapeutics.
